The Biopharmaceutical Excipients market is anticipated to reach USD 2.4 Billion by 2032 at a CAGR 5.6% during the forecast period 2023-2032. A biopharmaceutical excipient is an inert drug delivery substance methodologically prepared with the medically active ingredient that further processes the drug delivery in the recipient's system. Excipients are stable and reproducible, pharmacologically inert, and cost-effective. They are composed of corn, wheat, sugar, minerals, and othersuch substances.
Biopharmaceutical excipients are available in different types of formulations such as capsules, topical creams, tablets, gels, injectables, and transdermal patches. In addition, these types of excipients provide accurate dosing of potent ingredients, offer mechanical strength to the ingredients, increase the surface area for the active ingredient, protect the medication from the environmental reaction, and mask the texture, smell, and taste of the drug.
Biopharmaceutical excipients are experiencing high demand due to increasing production of drugs during the pandemic outbreak, supporting government policies, and introduction of partial subsidy schemes minimizing production costs. The outbreak of the coronavirus across the globe created huge demands for specialized medicines that further drive excipient sales. The market players offer specific excipients for biopharmaceuticals that are composed of sucrose, sodium chloride, magnesium chloride hexahydrate, and disodium edetate dehydrate. Moreover, the increasing number of patients getting diagnosed with chronic disease is creating possibilities for the biopharmaceutical excipients manufacturers. The market growth is driven by the above-mentioned factors and is expected to accelerate during the forecast period.
COVID-19 Analysis
COVID-19 has impacted various industry verticals across the globe. The pandemic spread led to the closure of manufacturing units, transportation of raw materials, and distribution channels throughout the globe. During the initial days of lockdown, the production of drugs and health-related products ceased to avoid the spread of disease. The government authorities mandate the guidelines to restrict the ongoing R&D activities and biopharmaceutical manufacturing. However, the demand for generic and specialty medicines rose due to the increasing number of corona cases and existing patients diagnosed with chronic diseases. The pharmaceutical production was carried out with special guidelines, and the research laboratories were functional with a limited workforce.
The increasing number of COVID cases impulsed government authorities to manufacture drugs in a large volume to treat the affected patients. However, the manufacturing units were working with a low workforce as the employees and daily wagers traveled back to their hometown, limiting the production capacity of the organizations. The government authorities promised to provide meals, insurance and, higher wages for immediate deployment of the workforce in pharmaceutical manufacturing units. This created an opportunity for the biopharmaceutical excipient manufacturers and augmented the product sales during the pandemic outbreak.
Drivers
Increasing demand for sucrose-based excipients for medicine formulation
Growing demand for lipid excipient for the production of COVID vaccines
Rising demand for stable and economical excipient for generic medicines
Market Restraints
Concerns pertaining to the adverse effects of biopharmaceutical excipients
Technology Analysis
Nanotechnology is significantly being used in the development of advanced excipients. The use of nanotechnology will alter the size of the excipients from capsules and tablets to solidified micelles. The emergence of such technology aims to improve the drug delivery of medicines. Additionally, nanotech can be used to improve the hindered release of formulations. According to a study in the Journal of Pharmaceutical Sciences, the porous magnesium carbonate excipient can control the release of active pharmaceutical ingredients. Moreover, the introduction of 3D printing aims at augmenting the production of new generation excipient. It is used for the fabrication of the immediate release pharmaceutical tablets. The emergence of such technologies is propelling the biopharmaceutical excipients market.
North America
Increasing demand for medicines across the region is driving the North America biopharmaceutical excipients market
North America held the largest share of the global biopharmaceutical excipient market in 2020 due to the increasing manufacturing of generic and specialty drugs, growing investments in R&D activities, and the establishment of technically advanced research centers. The prominent players are involved in the diversification of their distribution channel and expansion of their manufacturing facilities across the region, engaging in mergers and acquisitions, and introduction of new product variants for business growth.
Asia Pacific
Supportive government policiesarepropelling the Asia-Pacific biopharmaceutical excipient market
The Asia-Pacific biopharmaceutical excipients market is projected to be the fastest-growing regional market due to the up-gradation of pharmaceutical manufacturing units, an increasing number of biopharmaceutical investors, supportive government policies for the production of medicines, and deployment of nanotech labs for innovation of advanced excipients. Moreover, other factors supporting the biopharmaceutical excipient market include substantial investments by industry players and the innovation of machines to produce a high volume of excipients in a limited time. Such factors are expected to propel the market growth during the forecast period.
Competitive Landscape
Colorcon (US) is one of the leading players in the biopharmaceutical excipients market, offering products such as starch 1500, startab, starcap, and ambaerlite, and duolite ion exchange resin. These excipients can stabilize moisture-sensitive drugs, offer low dose content uniformity, and are compliant with regulatory standards. In addition, products such as startab are compressible starch excipients that provide excellent flow and compressibility. The product is manufactured at GMP facilities and is compliant with government guidelines. Moreover, satrcap a maize starch excipient, offers high flow and low adhesion functionality. Starcap provides lasting stability to reactive drugs. Furthermore, the company introduced ion-exchange resin-based excipients that are applied for taste masking, solubility enhancing, drug stabilizing, and abuse deterrence.
Industry players are coming up with various commercial strategies to augment their market footprint. The organizations are capitalizing on innovations and product launches to expand their product portfolio, further driving the biopharmaceutical excipients market. In addition, the market players are offering contractual agreements, approvals from government authorities, collaborations, funding, product promotions, and partnering with other players to expand their global footprint.
List of Key Companies Covered in this Report:
Recent Developments
In April 2021,DFE Pharma (Germany) launched an excipient solution for biopharma,BioHale Sucrose,that offers exceptional purity stabilization for biologics.
In May 2019,Colorcon, Inc. (US) launched a starch-based tableting excipient for direct compression. The product is developed using particle engineering and is approved by regulatory authorities across the globe.
In March 2020, Signet Chemical Corporation Pvt. Ltd(India) changed its name to Signet Excipients Pvt. Ltd.Furthermore, in November 2020, the company was acquired by IMCD N.V.(Netherlands),a leading global distributor of specialty chemicals and ingredients.
In September 2020,Sigachi Industries (India), a cellulose-based excipient manufacturer, filed an IPO worth USD 600 million.
In March 2020, Roquette (France) launched an online technical platform,"Innovation Hub,"for researchers and developersto formulate ideas and information exchange.
Report Overview
The study covers the existing short-term and long-term market effect, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID on the market.
| Report Attribute/Metric | Details |
| Market Size | USD 2.4 Billion |
| CAGR | 5.6% |
| Base Year | 2020 |
| Forecast Period | 2023-2032 |
| Historical Data | 2018-2019 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment Procedure, Cellulite Type and End Use |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Merck KGaA (Germany), Colorcon (BPSI Holdings Inc.) (U.S.), BASF SE(Germany), Associated British Foods plc (UK), Signet Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited (Hyderabad), Spectrum Chemical Manufacturing Corp. (U.S.), Roquette Frères (Roquette Frères) Clariant (Switzerland), DFE Pharma (Germany) J. Rettenmaier&SöhneGmbh + Co Kg (Germany) Evonik Industries AG (Germany) |
| Key Market Opportunities | The emrgence of 3D pinters for customized drug manufacturing |
| Key Market Drivers | Increasing demand of sucrose based excipients for medicine formulation |
Biopharmaceutical Excipients Market Highlights:
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
